A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry

References

• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Gallego P, Roldan V, Marín F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost. 2013 Dec;110(6):1189–1198.
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost. 2017 Jun 27;117(7):1448–1454.
   PubMed Web of Science ®Google Scholar
• Joppa SA, Salciccioli J, Adamski J, et al. A practical review of the emerging direct anticoagulants. Lab Monit Reversal Agents. J Clin Med. 2018 Feb 11;7(2):E29.
   PubMed Web of Science ®Google Scholar
• Chao TF, Joung B, Takahashi Y, et al. Focused update consensus guidelines of the asia pacific heart rhythm society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost. 2022 Jan;122(1):20–47.
   Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Benz AP, Eikelboom JW, Yusuf S, et al. Long-Term treatment with apixaban in patients with atrial fibrillation: outcomes during the open-label extension following AVERROES. Thromb Haemost. 2021 Apr;121(4):518–528.
   PubMedGoogle Scholar
• de Vries TAC, Hirsh J, Xu K, et al. Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?-A systematic review. Thromb Haemost. 2020 Sep;120(9):1323–1329.
   PubMedGoogle Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet Lond Engl. 2014 Mar 15;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Chan YH, Lee HF, Chao TF, et al. Real-world comparisons of direct oral anticoagulants for stroke prevention in Asian patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2019 Dec;33(6):701–710.
   PubMed Web of Science ®Google Scholar
• Bertomeu-González V, Anguita M, Moreno-Arribas J, et al. Quality of anticoagulation with vitamin K antagonists. Clin Cardiol. 2015 Jun;38(6):357–364.
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National registry of atrial fibrillation. JAMA. 2001 Jun 13;285(22):2864–2870.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263–272.
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest. 2010 Nov;138(5):1093–1100.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost JTH. 2005 Apr;3(4):692–694.
   PubMed Web of Science ®Google Scholar
• Carmo J, Moscoso Costa F, Ferreira J, et al. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost. 2016 Sep 27;116(4):754–763.
   PubMed Web of Science ®Google Scholar
• Bai Y, Deng H, Shantsila A, et al. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis. Stroke. 2017 Apr;48(4):970–976.
   PubMed Web of Science ®Google Scholar
• Proietti M, Romanazzi I, Romiti GF, et al. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2018 Jan;49(1):98–106.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhuang X, Long M, et al. Efficacy and safety of edoxaban in nonvalvular atrial fibrillation: a meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2015 Dec;24(12): 2710–2719.
   PubMed Web of Science ®Google Scholar
• Amin A, Stokes M, Wu N, et al. Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients. Curr Med Res Opin. 2013 Oct;29(10):1253–1261.
   PubMed Web of Science ®Google Scholar
• Li G, Lip GYH, Marcucci M, et al. The number needed to treat for net effect (NNTnet) as a metric for measuring combined benefits and harms. J Clin Epidemiol. 2020 Sep;125:100–107.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995 Feb 1;273(5):408–412.
   PubMed Web of Science ®Google Scholar
• Sackett DL, Wennberg JE. Choosing the best research design for each question. BMJ. 1997 Dec 20;315(7123):1636.
   PubMed Web of Science ®Google Scholar
• Rainville T, Laskine M, Durand M. Use of modified intention-to-treat analysis in studies of direct oral anticoagulants and risk of selection bias: a systematic review. BMJ Evid-Based Med. 2019 Apr;24(2):63–69.
   PubMedGoogle Scholar
• Mahajan R. Real world data: additional source for making clinical decisions. Int J Appl Basic Med Res. 2015;5(2):82.
   PubMedGoogle Scholar
• Ntaios G, Papavasileiou V, Makaritsis K, et al. Real-world setting comparison of nonvitamin-k antagonist oral anticoagulants versus vitamin-k antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017 Sep;48(9):2494–2503.
   PubMed Web of Science ®Google Scholar
• Van Ganse E, Danchin N, Mahé I, et al. Comparative safety and effectiveness of oral anticoagulants in nonvalvular atrial fibrillation: the NAXOS study. Stroke. 2020 Jul;51(7):2066–2075.
   PubMed Web of Science ®Google Scholar
• Steffel J, Collins R, Antz M, et al. European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2021 Oct 9;23(10): 1612–1676.
   Google Scholar
• Deitelzweig S, Bergrath E, Di Fusco M, et al. Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis. Future Cardiol. 2022 May;18(5):393–405.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018 Nov;154(5):1121–1201.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian AV, Zhang Y, et al. Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding. JAMA Network Open. 2021 Aug 16;4(8):e2120064.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020 [Cited 2021 Feb 1];42(5):373–498.
   Web of Science ®Google Scholar
• Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the “Atrial fibrillation better care” pathway in patients with atrial fibrillation: impact on clinical outcomes-A systematic review and meta-analysis of 285,000 patients. Thromb Haemost. 2021 Mar;122(3):406–414.
   Web of Science ®Google Scholar